Genetic alterations in lymphoblastic leukaemia<b> / lymphoma – a practical guide to WHO HAEM5</b>-Reference-Cited by-同舟云学术

Genetic alterations in lymphoblastic leukaemia / lymphoma – a practical guide to WHO HAEM5

Published:2024-03-04 Issue:1 Volume:36 Page:39-45
ISSN:1863-5490
Container-title:Medizinische Genetik
language:en
Short-container-title:

Author:

Steinemann Doris¹^ORCID,Dawidowska Małgorzata²^ORCID,Russell Lisa J³^ORCID,Harrison Christine J⁴^ORCID,Göhring Gudrun⁵^ORCID

Affiliation:

1. Hannover Medical School Department of Human Genetics Hannover Germany

2. Institute of Human Genetics Department of Molecular and Clinical Genetics Poznan Poland

3. Newcastle University Centre for Cancer Biosciences Institute Newcastle upon Tyne UK

4. Newcastle University Centre for Cancer Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle upon Tyne UK

5. Amedes genetics MVZ wagnerstibbe für Laboratoriumsmedizin, Hämostaseologie, Humangenetik und Mikrobiologie Hannover Germany

Abstract

Abstract We present a practical guide for analyzing the genetic aspects of lymphoblastic leukaemia/lymphoma according to the 5th edition of the World Health Organization (WHO) classification of haematolymphoid neoplasms (WHO-HAEM5) issued in 2024. The WHO-HAEM5 acknowledges the increasing importance of genetics in the diagnosis of lymphoid neoplasia. Classification is based on the established genetic subtypes according to cell lineage, with precursor cell neoplasms followed by mature malignancies. This guide describes those genetic abnormalities in acute precursor B- and T-cell neoplasms required for risk stratification, and for treatment, providing diagnostic algorithms under the headings of ‘essential’ and ‘desirable’ diagnostic criteria.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/medgen-2024-2007/pdf

Reference46 articles.

1. WHO. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version ahead of print]. WHO classification of tumours series. 2022. 5th ed.; vol. 11.

2. Maitra, A., et al., Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol, 2001. 115(6): p. 868–75.

3. Moricke, A., et al., Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016. 127(17): p. 2101–12.

4. Schrappe, M., et al., Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011. 118(8): p. 2077–2084.

5. Hunger, S. P., et al., Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol, 2012. 30(14): p. 1663–9.